Kindstar Globalgene Technology (HKG:9960) acquired a 49% equity interest in AnchorDx Inc. from AnchorDx Group HK.
The company settled the consideration for the acquisition by issuing 15,869,521 shares to WXHY Anchor Investment and 43,561,835 shares to OrbiMed Asia Partner at HK$1.42 apiece, a Friday Hong Kong bourse filing said.
Meanwhile Kindstar Global Medical Technology (Wuhan), a subsidiary of the company, also acquired 100% equity interest in Guangzhou Kangcheng Weiye Biotechnology from AnchorDx Group HK.
The group funded the acquisition consideration through internal resources and external funding.
After the completion, Guangzhou Kangcheng Weiye Biotechnology became a subsidiary of the company.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。